small molecule

EMFLAZA

DEFLAZACORT

Loss of exclusivityJune 2026FDA regulatory exclusivity expiry

CompanyPTC Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand name	EMFLAZA
Active ingredient	DEFLAZACORT
Strength	30MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2017
Marketing status	RX

Regulatory exclusivity

Code	Expires
ODE-252	June 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Regulatory exclusivity

More from PTC Therapeutics